Edmund Harrigan - Net Worth and Insider Trading
Edmund Harrigan Net Worth
The estimated net worth of Edmund Harrigan is at least $18 Million dollars as of 2024-04-27. Edmund Harrigan is the Director of Karuna Therapeutics Inc and owns about 55,163 shares of Karuna Therapeutics Inc (KRTX) stock worth over $18 Million. Edmund Harrigan is the Director of ACADIA Pharmaceuticals Inc and owns about 1,000 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $16,710. Edmund Harrigan is also the Director of PhaseBio Pharmaceuticals Inc and owns about 6,000 shares of PhaseBio Pharmaceuticals Inc (PHASQ) stock worth over $1. Details can be seen in Edmund Harrigan's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Edmund Harrigan has not made any transactions after 2020-12-03 and currently still holds the listed stock(s).
Transaction Summary of Edmund Harrigan
Edmund Harrigan Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Edmund Harrigan owns 5 companies in total, including Incyte Corp (INCY) , Karuna Therapeutics Inc (KRTX) , and ACADIA Pharmaceuticals Inc (ACAD) among others .
Click here to see the complete history of Edmund Harrigan’s form 4 insider trades.
Insider Ownership Summary of Edmund Harrigan
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INCY | Incyte Corp | 2023-09-29 | director |
| KRTX | Karuna Therapeutics Inc | 2020-08-12 | director |
| ACAD | ACADIA Pharmaceuticals Inc | 2019-06-26 | director |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2020-12-03 | director |
| BLCM | Bellicum Pharmaceuticals Inc | 2018-02-20 | director |
Edmund Harrigan Latest Holdings Summary
Edmund Harrigan currently owns a total of 3 stocks. Among these stocks, Edmund Harrigan owns 55,163 shares of Karuna Therapeutics Inc (KRTX) as of August 12, 2020, with a value of $18 Million and a weighting of 99.91%. Edmund Harrigan owns 1,000 shares of ACADIA Pharmaceuticals Inc (ACAD) as of August 16, 2016, with a value of $16,710 and a weighting of 0.09%. Edmund Harrigan also owns 6,000 shares of PhaseBio Pharmaceuticals Inc (PHASQ) as of December 3, 2020, with a value of $1 and a weighting of 0%.
Latest Holdings of Edmund Harrigan
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KRTX | Karuna Therapeutics Inc | 2020-08-12 | 55,163 | 329.83 | 18,194,412 |
| ACAD | ACADIA Pharmaceuticals Inc | 2016-08-16 | 1,000 | 16.71 | 16,710 |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2020-12-03 | 6,000 | 0.00 | 1 |
Holding Weightings of Edmund Harrigan
Edmund Harrigan Form 4 Trading Tracker
According to the SEC Form 4 filings, Edmund Harrigan has made a total of 3 transactions in Karuna Therapeutics Inc (KRTX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Karuna Therapeutics Inc is the sale of 10,000 shares on August 12, 2020, which brought Edmund Harrigan around $833,200.
According to the SEC Form 4 filings, Edmund Harrigan has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 1,000 shares on August 16, 2016, which cost Edmund Harrigan around $32,970.
According to the SEC Form 4 filings, Edmund Harrigan has made a total of 1 transactions in PhaseBio Pharmaceuticals Inc (PHASQ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in PhaseBio Pharmaceuticals Inc is the acquisition of 6,000 shares on December 3, 2020, which cost Edmund Harrigan around $24,720.
Insider Trading History of Edmund Harrigan
- 1
Edmund Harrigan Trading Performance
GuruFocus tracks the stock performance after each of Edmund Harrigan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Edmund Harrigan is -10.06%. GuruFocus also compares Edmund Harrigan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Edmund Harrigan within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Edmund Harrigan's insider trading performs compared to the benchmark.
Performance of Edmund Harrigan
Average Return
-27.68%
Outperforming Transactions
0%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -6.18 | -10.06 | 3.74 | -27.68 | -62.47 | -49.65 |
| Relative Return to S&P 500(%) | -6.5 | -12.11 | -7.32 | -46.22 | -72.26 | -58.5 |
Edmund Harrigan Ownership Network
Ownership Network List of Edmund Harrigan
Ownership Network Relation of Edmund Harrigan
Edmund Harrigan Owned Company Details
What does Incyte Corp do?
Who are the key executives at Incyte Corp?
Edmund Harrigan is the director of Incyte Corp. Other key executives at Incyte Corp include EVP & Chief Medical Officer Steven H Stein , EVP GPS & BD & & Licensing Vijay K Iyengar , and Principal Accounting Officer Thomas Tray .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Edmund Harrigan made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net sale of 57,275 shares made by Steven H Stein , a net sale of 24,981 shares made by Vijay K Iyengar , and a net sale of 2,500 shares made by Thomas Tray .
In summary, during the past 3 months, insiders sold 0 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 155,648 shares of Incyte Corp (INCY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 155,648 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Edmund Harrigan Mailing Address
Above is the net worth, insider trading, and ownership report for Edmund Harrigan. You might contact Edmund Harrigan via mailing address: C/o Acadia Pharmaceuticals Inc., 12830 El Camino Real, Suite 400, San Diego Ca 92130.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
